JPWO2019186369A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019186369A5 JPWO2019186369A5 JP2020551266A JP2020551266A JPWO2019186369A5 JP WO2019186369 A5 JPWO2019186369 A5 JP WO2019186369A5 JP 2020551266 A JP2020551266 A JP 2020551266A JP 2020551266 A JP2020551266 A JP 2020551266A JP WO2019186369 A5 JPWO2019186369 A5 JP WO2019186369A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antigen
- dose
- binding fragment
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 47
- 108091007172 antigens Proteins 0.000 claims description 47
- 102000038129 antigens Human genes 0.000 claims description 47
- 239000008194 pharmaceutical composition Substances 0.000 claims description 34
- 108010086617 ligelizumab Proteins 0.000 claims description 30
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 24
- 229940071643 Prefilled Syringe Drugs 0.000 claims description 16
- 238000007920 subcutaneous administration Methods 0.000 claims description 15
- 108010049535 anti-IgE antibodies Proteins 0.000 claims description 13
- 108090001123 antibodies Proteins 0.000 claims description 6
- 102000004965 antibodies Human genes 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 208000010201 Exanthema Diseases 0.000 claims description 4
- 229940065725 Leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 claims description 4
- 206010037844 Rash Diseases 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 201000005884 exanthem Diseases 0.000 claims description 4
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 4
- 102000003984 Aryl hydrocarbon receptors Human genes 0.000 claims description 2
- 108090000448 Aryl hydrocarbon receptors Proteins 0.000 claims description 2
- 206010072757 Chronic spontaneous urticaria Diseases 0.000 claims description 2
- 229950009923 Ligelizumab Drugs 0.000 claims description 2
- 208000006641 Skin Disease Diseases 0.000 claims description 2
- 230000035852 Tmax Effects 0.000 claims description 2
- 230000035493 absolute bioavailability Effects 0.000 claims description 2
- 230000001058 adult Effects 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 101700060378 sec9 Proteins 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 230000002459 sustained Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229940090047 Auto-Injector Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862647928P | 2018-03-26 | 2018-03-26 | |
| US62/647,928 | 2018-03-26 | ||
| US201962811800P | 2019-02-28 | 2019-02-28 | |
| US62/811,800 | 2019-02-28 | ||
| PCT/IB2019/052408 WO2019186369A1 (en) | 2018-03-26 | 2019-03-25 | Methods of treating chronic spontaneous urticaria using ligelizumab |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523881A JP2021523881A (ja) | 2021-09-09 |
| JPWO2019186369A5 true JPWO2019186369A5 (ru) | 2022-03-31 |
Family
ID=66476672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551266A Pending JP2021523881A (ja) | 2018-03-26 | 2019-03-25 | リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210115155A1 (ru) |
| EP (1) | EP3773904A1 (ru) |
| JP (1) | JP2021523881A (ru) |
| KR (1) | KR20200135826A (ru) |
| CN (1) | CN112203724A (ru) |
| AU (1) | AU2019244666A1 (ru) |
| CA (1) | CA3094749A1 (ru) |
| IL (1) | IL277474A (ru) |
| WO (1) | WO2019186369A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021250546A1 (en) | 2020-06-09 | 2021-12-16 | University Of Washington | Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria |
| WO2021250533A1 (en) * | 2020-06-09 | 2021-12-16 | Novartis Ag | Methods of treatment using omalizumab or ligelizumab |
| EP4355362A1 (en) * | 2021-06-14 | 2024-04-24 | Novartis AG | Pharmaceutical formulation containing an anti-ige antibody |
| CN117897409A (zh) * | 2021-08-13 | 2024-04-16 | 基因泰克公司 | 抗类胰蛋白酶抗体的给药 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0200429D0 (en) * | 2002-01-09 | 2002-02-27 | Novartis Ag | Organic compounds |
| CN1829806A (zh) * | 2003-02-01 | 2006-09-06 | 唐纳士公司 | 产生高亲和力抗体的方法 |
| PL1610820T5 (pl) * | 2003-04-04 | 2014-01-31 | Genentech Inc | Preparaty zawierające wysokoskoncentrowane przeciwciała i białka |
| AU2004315197B2 (en) * | 2004-02-02 | 2009-06-04 | Tanox, Inc. | Identification of novel IgE epitopes |
| EP2726080A1 (en) * | 2011-06-29 | 2014-05-07 | Allergan, Inc. | Alcaftadine for use in the treatment of urticaria |
| TW201343176A (zh) * | 2012-04-16 | 2013-11-01 | Novartis Ag | 使用ｉｌ－１７拮抗劑治療乾癬性關節炎之方法 |
| CN104547325A (zh) * | 2015-01-21 | 2015-04-29 | 李健 | 一种治疗慢性特发性荨麻疹的药物组合物及其应用 |
-
2019
- 2019-03-25 AU AU2019244666A patent/AU2019244666A1/en not_active Abandoned
- 2019-03-25 CN CN201980021766.9A patent/CN112203724A/zh active Pending
- 2019-03-25 EP EP19723202.8A patent/EP3773904A1/en active Pending
- 2019-03-25 JP JP2020551266A patent/JP2021523881A/ja active Pending
- 2019-03-25 KR KR1020207030057A patent/KR20200135826A/ko not_active Application Discontinuation
- 2019-03-25 CA CA3094749A patent/CA3094749A1/en active Pending
- 2019-03-25 WO PCT/IB2019/052408 patent/WO2019186369A1/en unknown
- 2019-03-25 US US17/041,291 patent/US20210115155A1/en not_active Abandoned
-
2020
- 2020-09-21 IL IL277474A patent/IL277474A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6754857B2 (ja) | Ｉｌ−４ｒ阻害剤の投与によるアレルギー処置方法およびアレルゲン特異的免疫療法の向上方法 | |
| JP6416336B2 (ja) | 高濃度抗体製剤 | |
| ES2978990T3 (es) | Métodos de reducción del riesgo cardiovascular | |
| JP2020143115A (ja) | 片頭痛の治療または予防法 | |
| JP6596014B2 (ja) | 爪および頭皮乾癬の治療方法 | |
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| JP2008528638A5 (ru) | ||
| JP2017512193A (ja) | Ｉｌ−４ｒアンタゴニストを投与することによる皮膚感染を処置するための方法 | |
| JP2022543612A (ja) | Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法 | |
| US11248044B2 (en) | Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor | |
| JP2022126791A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| JP2019521156A5 (ru) | ||
| WO2024097714A1 (en) | Methods for treating hand and foot dermatitis by administering an il-4r antagonist | |
| JPWO2019186369A5 (ru) | ||
| RU2020134794A (ru) | Способы лечения хронической спонтанной крапивницы с применением лигелизумаба | |
| KR20210104744A (ko) | 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법 | |
| TW201828984A (zh) | 使用介白素-17(il-17)拮抗劑治療痤瘡的方法 | |
| WO2024112935A1 (en) | Methods for improving bone growth by administering an il-4r antagonist | |
| JPWO2020245766A5 (ru) | ||
| TW202432600A (zh) | 用於治療肥胖症之方法 | |
| CA3187136A1 (en) | Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists | |
| WO2021111377A2 (en) | Methods of treating lichen planus using interleukin-17 (il-17) antagonists | |
| TW202206457A (zh) | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 | |
| EA045866B1 (ru) | Состав терапевтического антитела | |
| KR20240125973A (ko) | 바스 증후군 치료를 위한 방법 및 조성물 |